Drugs / IMVT-1402
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT07286006 | Jan 2026 → Mar 2030 expected | Graves disease | Immunovant Sciences GmbH | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06979531 | Jun 2025 → Jul 2028 expected | Sjogren syndrome | Immunovant Sciences GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT07018323 | Jun 2025 → May 2027 expected | Graves disease | Immunovant Sciences GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT06980805 | Feb 2025 → Oct 2026 expected | chronic cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus | Immunovant Sciences GmbH | Active not recruiting | Missed primary |
| Phase 2 | NCT06754462 | Jan 2025 → Sep 2027 expected | rheumatoid arthritis | Immunovant Sciences GmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06727604 | Dec 2024 → Jun 2028 expected | Graves disease | Immunovant Sciences GmbH | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07039916 | May 2025 → Dec 2027 expected | generalized myasthenia gravis | Immunovant Sciences GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMVT-1402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07286006 ↗ |
| Route | Subcutaneous | “600 mg SC QW for 52 weeks” NCT06727604 ↗ |